Pancreatic ductal adenocarcinoma (PDAC) has been recognized as one of the most aggressive and lethal types of cancer worldwide. The absence of specific symptoms in the early stages of the disease, combined with the rapid tumour growth and the limitations of the available imaging techniques, delays the diagnosis of PDAC, revealing it only when an advanced and usually metastasized stage has already been reached. At this point, surgical resection is too risky, and chemotherapy is not totally effective due to the strong resistance of the PDAC to common anti-tumoral drugs, giving patients a five-year survival rate of less than 10%. PDAC onsets from the progressive accumulation of genetic aberrations in the pancreatic ductal cells, that enhance cancer cell survival, proliferation, and immune evasion, while disrupting normal cell-cycle control.